Yorkville Advisors Global LP Takes $1.31 Million Position in Alignment Healthcare, Inc. $ALHC

Yorkville Advisors Global LP bought a new position in Alignment Healthcare, Inc. (NASDAQ:ALHC) during the third quarter, Holdings Channel reports. The fund bought 75,000 shares of the company’s stock, valued at approximately $1,309,000. Alignment Healthcare makes up 0.3% of Yorkville Advisors Global LP’s portfolio, making the stock its 12th biggest holding.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in Alignment Healthcare by 5.0% during the third quarter. Vanguard Group Inc. now owns 13,968,584 shares of the company’s stock worth $243,752,000 after acquiring an additional 664,769 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Alignment Healthcare by 167.3% during the third quarter. Wellington Management Group LLP now owns 11,089,727 shares of the company’s stock valued at $193,516,000 after purchasing an additional 6,940,277 shares in the last quarter. Hood River Capital Management LLC increased its stake in shares of Alignment Healthcare by 6.0% during the second quarter. Hood River Capital Management LLC now owns 5,517,336 shares of the company’s stock valued at $77,243,000 after purchasing an additional 311,424 shares in the last quarter. 8 Knots Management LLC lifted its holdings in shares of Alignment Healthcare by 6.4% during the second quarter. 8 Knots Management LLC now owns 5,015,881 shares of the company’s stock valued at $70,222,000 after purchasing an additional 300,409 shares during the last quarter. Finally, Invesco Ltd. boosted its position in shares of Alignment Healthcare by 7.1% in the 3rd quarter. Invesco Ltd. now owns 4,466,630 shares of the company’s stock worth $77,943,000 after purchasing an additional 296,101 shares in the last quarter. 86.19% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Alignment Healthcare

In related news, CEO John E. Kao sold 605,648 shares of Alignment Healthcare stock in a transaction on Monday, December 29th. The stock was sold at an average price of $18.74, for a total transaction of $11,349,843.52. Following the transaction, the chief executive officer directly owned 2,234,294 shares in the company, valued at approximately $41,870,669.56. The trade was a 21.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Robert L. Scavo sold 69,541 shares of the business’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $18.74, for a total value of $1,303,198.34. Following the sale, the insider directly owned 503,014 shares of the company’s stock, valued at $9,426,482.36. This represents a 12.15% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 2,096,821 shares of company stock worth $40,774,893 in the last 90 days. 6.60% of the stock is currently owned by insiders.

Alignment Healthcare Trading Up 2.3%

Alignment Healthcare stock opened at $17.92 on Wednesday. Alignment Healthcare, Inc. has a 52-week low of $11.63 and a 52-week high of $23.87. The company has a market cap of $3.66 billion, a P/E ratio of -1,790.21, a P/E/G ratio of 2.56 and a beta of 1.18. The company has a quick ratio of 1.71, a current ratio of 1.71 and a debt-to-equity ratio of 1.80. The business has a 50-day simple moving average of $20.62 and a two-hundred day simple moving average of $18.79.

Alignment Healthcare (NASDAQ:ALHC) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Alignment Healthcare had a negative net margin of 0.02% and a negative return on equity of 0.49%. The firm’s revenue was up 44.4% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.16) earnings per share. Analysts predict that Alignment Healthcare, Inc. will post -0.69 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ALHC. JPMorgan Chase & Co. upped their price target on Alignment Healthcare from $23.00 to $26.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Robert W. Baird set a $28.00 price objective on shares of Alignment Healthcare in a research report on Friday, January 30th. Piper Sandler upped their target price on shares of Alignment Healthcare from $20.00 to $30.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Alignment Healthcare in a report on Wednesday, January 21st. Finally, KeyCorp reiterated an “overweight” rating and set a $28.00 target price on shares of Alignment Healthcare in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $24.56.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.